ASMB - Assembly Biosciences, Inc.
| Previous Close | 15.10 |
| Open | 15.23 |
| Bid | 15.44 x 900 |
| Ask | 15.60 x 900 |
| Day's Range | 14.85 - 15.72 |
| 52 Week Range | 13.13 - 48.91 |
| Volume | 50,276 |
| Avg. Volume | 351,500 |
| Market Cap | 397.81M |
| Beta (3Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•12 days ago
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•12 days ago
Assembly Biosciences: 1Q Earnings Snapshot
On a per-share basis, the Carmel, Indiana-based company said it had a loss of $1.05. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- Insider Monkey•12 days ago
Here’s What Hedge Funds Think About Assembly Biosciences Inc (ASMB)
With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Assembly Biosciences Inc (NASDAQ:ASMB). Assembly Biosciences Inc (NASDAQ:ASMB) shareholders have […]
- Benzinga•18 days ago
The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...
- Zacks•22 days ago
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•last month
Here's Why Assembly Biosciences Is Slipping Today
Mid-stage clinical trial results weren't what some investors were looking for.
- Motley Fool•2 months ago
4 Biotech Stocks With Major Catalysts in April
April's about to shower biopharma investors with important updates that could move these stocks.
- Simply Wall St.•2 months ago
If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today
It hasn't been the best quarter for Assembly Biosciences, Inc. (NASDAQ:ASMB) shareholders, since the share price has fallen 19% in that time. But that doesn't undermine the rather lovely longer-termRead More...
- Zacks•3 months ago
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
- Zacks•4 months ago
Mylan (MYL) Jumps: Stock Rises 7.1%
Mylan (MYL) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Simply Wall St.•4 months ago
Assembly Biosciences, Inc. (NASDAQ:ASMB) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Insider Monkey•5 months ago
Here is What Hedge Funds Think About Assembly Biosciences Inc (ASMB)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
- Zacks•6 months ago
Amphastar Pharmaceuticals (AMPH) Catches Eye: Stock Jumps 6.7%
Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Simply Wall St.•6 months ago
Should You Worry About Assembly Biosciences Inc’s (NASDAQ:ASMB) CEO Pay?
Derek Small became the CEO of Assembly Biosciences Inc (NASDAQ:ASMB) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that Read More...
- Zacks•6 months ago
Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 months ago
Assembly Biosciences: 3Q Earnings Snapshot
On a per-share basis, the Carmel, Indiana-based company said it had a loss of 87 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Benzinga•7 months ago
Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade
Assembly Biosciences Inc (NASDAQ: ASMB ) shares have shed over one-fourth of their value since late September, creating an opportunity to buy the dip, B. Riley FBR said Monday. The Analyst Analyst Madhu ...
- Simply Wall St.•8 months ago
Shareholders Should Check The Ownership Structure Of Assembly Biosciences Inc (NASDAQ:ASMB)
Every investor in Assembly Biosciences Inc (NASDAQ:ASMB) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...
- Zacks•9 months ago
Assembly Biosciences (ASMB) Reports Q2 Loss, Misses Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -44.44% and -2.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•9 months ago
Assembly Biosciences: 2Q Earnings Snapshot
The Carmel, Indiana-based company said it had a loss of $1.30 per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
